Rubicon Research Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Rubicon Research Private Limited Pharmaceutical Export Portfolio Dataset — 13 Products, $94.9M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Rubicon Research Private Limited — Pharmaceutical Exporter Profile (2026) | 13 Products, $94.9M Trade | TransData Nexus

Rubicon Research Private Limited

Indian Pharmaceutical Exporter · Cardiovascular Specialist · $94.9M Total Trade · DGFT Verified

Rubicon Research Private Limited is an Indian pharmaceutical exporter with a total trade value of $94.9M across 13 products in 7 therapeutic categories. Based on 2,208 verified export shipments from Indian Customs (DGFT) records, Rubicon Research Private Limited is the #1 Indian exporter in 6 products including Metoprolol, Tramadol, Clonazepam. Top exports include Metoprolol ($26.6M), Tramadol ($11.4M), Iron ($9.1M).

Rubicon Research Private Limited — Export Portfolio & Destination Treemap

Rubicon Research Private Limited pharmaceutical export portfolio — 13 products across 7 therapeutic categories. Source: Indian Customs (DGFT).

Who is Rubicon Research Private Limited? — Company Overview & Market Position

Rubicon Research Private Limited, established on May 6, 1999, is a privately held Indian pharmaceutical company specializing in the development, manufacturing, and commercialization of generic and specialty formulations. The company is headquartered in Thane, Maharashtra, India, with its registered office at MedOne House, B-75, Road No. 33, Wagle Estate, Thane West, Thane, Maharashtra 400604.

As of the latest available data, Rubicon Research has an authorized capital of ₹238.99 crore and a paid-up capital of ₹21.045 crore. The company employs between 201 and 500 individuals, reflecting its substantial presence in the pharmaceutical sector.

In 2022, Rubicon Research reported a total export value of $94.9 million USD, with 2,208 shipments across 13 products in seven therapeutic categories. The company's top five products include Metoprolol ($26.6 million, 3.3% market share), Tramadol ($11.4 million, 3.0% market share), Iron ($9.1 million, 1.9% market share), Clonazepam ($8.4 million, 6.5% market share), and Potassium ($7.2 million, 1.1% market share).

What Does Rubicon Research Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Metoprolol$26.6M

Product Portfolio — Top 13 by Export Value

Rubicon Research Private Limited exports 13 pharmaceutical products across 7 therapeutic categories. Market leader (#1 exporter) in 6 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Metoprolol	Cardiovascular	$26.6M	532	3.3%	1
2	Tramadol	Analgesics & Antipyretics	$11.4M	228	3.0%	1
3	Iron	Vitamins & Supplements	$9.1M	322	1.9%	10
4	Clonazepam	CNS & Psychiatric	$8.4M	168	6.5%	1
5	Potassium	Nutritional Supplements	$7.2M	143	1.1%	4
6	Carvedilol	Cardiovascular	$6.6M	199	6.7%	7
7	Amiodarone	Cardiovascular	$5.4M	108	7.2%	2
8	Isosorbide	Cardiovascular	$4.9M	146	10.9%	3
9	Nicotine	Other	$4.7M	94	31.5%	1
10	Diclofenac	Analgesics & Antipyretics	$4.7M	93	1.3%	3
11	Nitroglycerin	Cardiovascular	$2.6M	92	26.6%	1
12	Loperamide	Gastrointestinal	$2.4M	48	3.2%	1
13	Bisoprolol	Cardiovascular	$1.1M	35	1.3%	11

Rubicon Research Private Limited exports 13 pharmaceutical products across 7 therapeutic categories with a total export value of $94.9M. The company is the #1 Indian exporter in 6 products: Metoprolol, Tramadol, Clonazepam, Nicotine, Nitroglycerin and 1 more. The top category is Cardiovascular (49.7% of portfolio), followed by Analgesics & Antipyretics (16.9%), indicating a concentrated portfolio with the top 5 products accounting for 66.0% of total export value.

Rubicon Research Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Rubicon Research operates multiple manufacturing facilities in India, including plants in Ambernath, Satara, and Pithampur. The Ambernath facility, commissioned in 2009, is US FDA-approved and specializes in oral solids manufacturing. The Satara facility, acquired in July 2021, focuses on oral liquid and nasal product manufacturing.

3Key Leadership

The leadership team at Rubicon Research includes:

Deep Mishra: Director since December 21, 2016.

Bangesh Chakrabarti: Director since December 21, 2016.

Pratibha Sudhir Pilgaonkar: Director since June 1, 2000.

Sudhir Dhirendra Pilgaonkar: Director since May 6, 1999.

Himanshu Nivsarkar: Director since December 17, 2012.

Pancham Navin Mukim: Director since January 27, 2017.

Parag Suganchand Sancheti: Director since January 27, 2017.

These individuals have been instrumental in steering the company's strategic direction and growth.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Rubicon Research Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Rubicon Research has established a significant presence in regulated markets, particularly in the United States. The company has over 28 approved products in the US, with more than 70 products in development and over 10 products under review with the US FDA.

In the European Union, the company has obtained EU GMP certificates, ensuring compliance with stringent manufacturing standards. Additionally, Rubicon Research has received WHO prequalification for certain products, facilitating access to global markets.

2Emerging Markets

Rubicon Research has expanded its footprint in emerging markets, including Africa, Latin America, and Southeast Asia. The WHO prequalification of some of its products has enabled the company to access these regions, enhancing its global reach and market penetration.

3Geographic Strategy

The company's geographic strategy demonstrates a balanced approach, with a strong focus on regulated markets such as the US and Europe, while also tapping into emerging markets through WHO prequalification. This diversification mitigates concentration risk and positions Rubicon Research for sustained growth across various regions.

Rubicon Research Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Rubicon Research's manufacturing facilities in Ambernath and Satara are US FDA-approved, reflecting the company's commitment to adhering to international quality standards. The company has a robust pipeline, with over 28 approved products in the US and more than 10 products under review with the US FDA.

2WHO & EU GMP

Rubicon Research has obtained WHO prequalification for certain products, facilitating access to global markets. The company has also secured EU GMP certificates, ensuring compliance with European manufacturing standards.

3CDSCO & Indian Regulatory

Rubicon Research holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), India's national regulatory authority. The company has also obtained state drug controller approvals and export No Objection Certificates (NOCs), enabling it to export pharmaceutical products internationally.

Recent Regulatory Actions

Rubicon Research Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Rubicon Research operates in a competitive landscape with several key players in the generic pharmaceutical sector. The company's focus on value-added products, strong R&D capabilities, and established presence in regulated markets provide it with a competitive edge. However, it faces competition from both established multinational corporations and emerging regional players.

2Key Differentiators

Rubicon Research's key differentiators include its extensive portfolio of over 28 approved products in the US, a pipeline of more than 70 products in development, and a commitment to quality evidenced by its US FDA-approved manufacturing facilities and EU GMP certifications.

3Strategic Position

Rubicon Research's strategic direction focuses on expanding its portfolio of generic and specialty products, leveraging its R&D capabilities to develop value-added formulations. The company's future outlook includes further penetration into regulated markets and emerging regions, supported by its robust manufacturing and regulatory compliance.

Buyer Due Diligence Brief — Evaluating Rubicon Research Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Rubicon Research has demonstrated a consistent track record in manufacturing and exporting pharmaceutical products, with a total export value of $94.9 million USD and 2,208 shipments across 13 products in seven therapeutic categories. The company's adherence to international quality standards and regulatory approvals underscores its reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications when considering Rubicon Research as a supplier:

FDA Approval: Confirm the company's US FDA-approved manufacturing facilities and product approvals.

WHO Prequalification: Verify the WHO prequalification status of relevant products.

EU GMP Certification: Ensure the company holds valid EU GMP certificates for applicable products.

Frequently Asked Questions — Rubicon Research Private Limited

How many pharmaceutical products does Rubicon Research Private Limited export from India?

Rubicon Research Private Limited exports 13 pharmaceutical products across 7 therapeutic categories. The top exports are Metoprolol ($26.6M), Tramadol ($11.4M), Iron ($9.1M), Clonazepam ($8.4M), Potassium ($7.2M). Total export value is $94.9M.

What is Rubicon Research Private Limited's total pharmaceutical export value?

Rubicon Research Private Limited's total pharmaceutical export value is $94.9M, based on 2,208 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Rubicon Research Private Limited the #1 Indian exporter?

Rubicon Research Private Limited is the #1 Indian exporter in 6 products: Metoprolol (3.3% market share), Tramadol (3.0% market share), Clonazepam (6.5% market share), Nicotine (31.5% market share), Nitroglycerin (26.6% market share), Loperamide (3.2% market share).

What therapeutic categories does Rubicon Research Private Limited cover?

Rubicon Research Private Limited exports across 7 therapeutic categories. The largest are Cardiovascular (49.7%, 6 products), Analgesics & Antipyretics (16.9%, 2 products), Vitamins & Supplements (9.6%, 1 products).

Get Full Rubicon Research Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.